Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 19.09.2026 | Accepted 20.09.2026 | Online 24.09.2026

EVIDENCE-BASED PHARMACOTHERAPY OF TYPE 2 DIABETES MELLITUS: NEW DRUG CLASSES AND TREATMENT STRATEGIES

Amelia R. Foster
Department of Clinical Pharmacology and Metabolic Medicine,
Bristol Institute of Biomedical Research, United Kingdom
amelia.foster@bibr-ac.uk

Abstract

Type 2 diabetes mellitus (T2DM) pharmacotherapy has shifted from a glucose-centric model toward an integrated strategy that simultaneously targets glycemic control, body weight, atherosclerotic cardiovascular disease (ASCVD), heart failure, and chronic kidney disease (CKD). This structured evidence-based review evaluates contemporary drug classes and treatment strategies with emphasis on the 2026 American Diabetes Association (ADA) Standards of Care and major cardiovascular and kidney outcome trials. A focused literature synthesis was conducted using international guidelines, consensus reports, and landmark randomized controlled trials evaluating metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonism, insulin, and adjunctive cardiorenal therapy. Current evidence supports phenotype-directed treatment rather than a uniform stepwise sequence. SGLT2 inhibitors are central when heart failure or CKD predominates, while GLP-1 RAs are prioritized in ASCVD and when substantial weight reduction is desired. Tirzepatide and high-efficacy GLP-1 RAs provide the greatest combined glucose- and weight-lowering effects among currently available noninsulin therapies. Cardiovascular outcome data now extend to oral semaglutide, while kidney outcome data from FLOW reinforce the role of semaglutide in T2DM with CKD. Finerenone adds kidney and cardiovascular protection in albuminuric CKD despite not being a glucose-lowering agent. Modern care therefore requires early combination therapy when appropriate, individualized sequencing, continuous reassessment, and attention to safety, tolerability, treatment burden, cost, and access. The therapeutic objective is no longer simply attainment of an HbA1c target; it is reduction of total cardiometabolic and kidney risk while preserving quality of life.

Keywords: type 2 diabetes mellitus; pharmacotherapy; SGLT2 inhibitors; GLP-1 receptor agonists; tirzepatide; cardiovascular risk; chronic kidney disease; precision treatment.

1. INTRODUCTION

Type 2 diabetes mellitus is a progressive metabolic disorder characterized by insulin resistance, impaired beta-cell function, inappropriate glucagon secretion, altered incretin biology, and complex interactions with obesity, cardiovascular disease, and chronic kidney disease. For many years, pharmacologic management was organized around sequential HbA1c reduction: metformin was initiated first, another glucose-lowering drug was added when glycemic control deteriorated, and insulin was introduced when oral therapy became insufficient. Although glucose lowering remains fundamental, this sequence does not fully

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

address the principal causes of morbidity and mortality in contemporary T2DM populations.

The therapeutic landscape changed when cardiovascular outcome trials demonstrated that selected glucose-lowering agents produce clinically meaningful benefits that cannot be explained solely by changes in HbA1c. SGLT2 inhibitors reduced heart-failure events and slowed progression of kidney disease, whereas several GLP-1 receptor agonists reduced major adverse cardiovascular events in patients at high cardiovascular risk (2,6,7,9-13). These findings led to a fundamental change in guideline logic: the presence of ASCVD, heart failure, CKD, obesity, or high cardiovascular risk can determine medication choice independently of baseline HbA1c and independently of metformin use (1,2).

The 2026 ADA Standards emphasize person-centered shared decision-making and require clinicians to consider cardiovascular and kidney effects, body weight, hypoglycemia risk, tolerability, cost, access, comorbidities, and patient preferences when selecting therapy (1). The same standards recognize tirzepatide and semaglutide as the most effective currently available pharmacologic options for combined glucose and weight reduction in many adults with T2DM and obesity, while SGLT2 inhibitors remain central for heart failure and CKD because of their robust organ-protective evidence (1,2).

At the same time, older agents remain clinically relevant. Metformin is effective, inexpensive, familiar, and associated with a low risk of hypoglycemia. DPP-4 inhibitors can be useful when simplicity and tolerability are priorities, while sulfonylureas and human insulin retain an important role where affordability dominates therapeutic choice. Thiazolidinediones provide durable glucose lowering but require careful selection because of weight gain, edema, and heart-failure concerns. Thus, evidence-based therapy does not simply replace older drugs with newer ones; it matches pharmacology to the patient phenotype and expected outcomes (1,3).

The aim of this article is to synthesize current evidence on established and emerging pharmacologic classes for T2DM and to present a practical, outcome-oriented framework for treatment selection. Special emphasis is placed on SGLT2 inhibitors, GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonism, cardiorenal risk reduction, rational combination therapy, and circumstances in which insulin remains essential.

2. MATERIALS AND METHODS

This article was designed as a structured narrative review using an IMRAD framework. Evidence selection prioritized international clinical practice guidelines, consensus reports, and randomized cardiovascular or kidney outcome trials that materially changed pharmacotherapy recommendations for adults with T2DM. The evidence base included the 2026 ADA Standards of Care, the ADA/EASD consensus report, and landmark trials of SGLT2 inhibitors, GLP-1 receptor agonists, tirzepatide, and finerenone (1-15).

Sources were selected according to four criteria: (1) direct relevance to pharmacologic treatment of T2DM; (2) high methodological quality or international guideline authority; (3) inclusion of clinically relevant outcomes such as HbA1c, body weight, cardiovascular events, heart-failure hospitalization, kidney disease progression, hypoglycemia, or treatment-limiting adverse effects; and (4) sufficient applicability to current clinical decision-making. Trials conducted in CKD populations that included participants without diabetes were retained when they provided class-defining evidence for SGLT2-mediated kidney protection relevant to T2DM care (12,13).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

Because this was not a quantitative meta-analysis, effect estimates from heterogeneous trials were not pooled. Instead, results were synthesized by therapeutic class and clinical phenotype. The review distinguishes glycemic efficacy from organ-specific outcome evidence and avoids indirect ranking of drugs when head-to-head outcome data are unavailable. Current recommendations were interpreted in a patient-centered framework that considers dominant clinical priorities, contraindications, hypoglycemia, body weight, treatment burden, and affordability.

3. RESULTS

3.1. Transition from glucose-centered therapy to outcome-centered therapy

The strongest contemporary finding is that drug selection in T2DM should not be based exclusively on HbA1c. In adults with established or high risk of ASCVD, medications with demonstrated cardiovascular benefit—principally selected GLP-1 RAs and SGLT2 inhibitors—should be incorporated into the treatment plan regardless of whether additional glucose lowering is required (1,2). For patients with heart failure, an SGLT2 inhibitor is preferred because the class consistently reduces heart-failure hospitalization. For patients with CKD and adequate kidney function for initiation, SGLT2 inhibitors are foundational, while GLP-1 RAs are increasingly supported when additional glycemic, weight, cardiovascular, or kidney benefit is needed (1,2,14).

This approach changes the meaning of "first-line" therapy. Metformin remains an appropriate and highly useful initial drug for many patients, but it is no longer a mandatory prerequisite before initiation of an organ-protective agent. Combination therapy can also be considered at diagnosis when monotherapy is unlikely to achieve individualized glycemic goals, thereby reducing therapeutic inertia (1,3).

3.2. Metformin and conventional glucose-lowering agents

Metformin continues to offer high glucose-lowering efficacy, low hypoglycemia risk, extensive clinical experience, and low cost. It is especially suitable for patients without a dominant ASCVD, heart-failure, or CKD indication who require reliable glycemic control and for use as background therapy in combination regimens. Gastrointestinal intolerance and vitamin B12 deficiency are relevant limitations, and kidney function must be considered when prescribing or continuing therapy (1,3).

DPP-4 inhibitors are generally weight neutral, well tolerated, and associated with minimal hypoglycemia when used without insulin or sulfonylureas. Their glucose-lowering potency is modest and they have not demonstrated the same cardiorenal outcome advantages as SGLT2 inhibitors or selected GLP-1 RAs. Sulfonylureas remain potent and inexpensive but cause more hypoglycemia and weight gain. Thiazolidinediones improve insulin sensitivity and can provide durable glycemic efficacy, but fluid retention, weight gain, and heart-failure risk constrain their use. These trade-offs explain why conventional agents remain useful but are increasingly selected according to context rather than as a fixed sequence (1,3).

Table 1. Comparative characteristics of major pharmacologic classes used in type 2 diabetes

Class	Glycemic efficacy	Weight effect	Hypoglycemia risk	Major outcome advantage	Important limitations

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

Class	Glycemic efficacy	Weight effect	Hypoglycemia risk	Major outcome advantage	Important limitations
Metformin	High	Neutral / modest loss	Low	Low cost; broad experience	GI intolerance; B12 deficiency; renal restrictions
SGLT2 inhibitors	Intermediate-high	Modest loss	Low	HF and CKD protection; CV benefit for selected agents	Genital infections; volume depletion; rare ketoacidosis
GLP-1 receptor agonists	High to very high	Substantial loss	Low	ASCVD benefit for selected agents; kidney benefit emerging/established	GI adverse effects; injection for most products; cost
Dual GIP/GLP-1 RA (tirzepatide)	Very high	Very substantial loss	Low	Powerful glycemic/weight efficacy; CV noninferior to dulaglutide	GI adverse effects; cost; long-term comparative data evolving
DPP-4 inhibitors	Modest	Neutral	Low	Simple oral dosing; tolerability	Lower efficacy; no major organ-protective advantage
Sulfonylureas	High	Gain	Moderate-high	Low cost; rapid glucose lowering	Hypoglycemia; weight gain; limited organ-specific benefit

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

Class	Glycemic efficacy	Weight effect	Hypoglycemia risk	Major outcome advantage	Important limitations
Thiazolidinediones	High	Gain / edema	Low	Insulin sensitization; durability	Edema, weight gain, HF concern, fractures
Insulin	Highest	Gain	High	Essential for severe hyperglycemia/catabolism and insulin deficiency	Hypoglycemia; weight gain; monitoring and injection burden

3.3. SGLT2 inhibitors: cardiorenal pharmacotherapy

SGLT2 inhibitors represent one of the most consequential advances in T2DM pharmacotherapy because their clinical value extends beyond glucose lowering. In EMPA-REG OUTCOME, empagliflozin reduced the primary cardiovascular composite and mortality in patients with T2DM and established cardiovascular disease (9). DECLARE-TIMI 58 broadened the evidence base to a large population with established ASCVD or multiple risk factors and showed a lower risk of cardiovascular death or hospitalization for heart failure, driven by fewer heart-failure hospitalizations (10).

Kidney outcome trials established a second major therapeutic domain. CREDENCE demonstrated that canagliflozin lowered the risk of kidney failure and cardiovascular events in patients with T2DM and albuminuric CKD (11). DAPA-CKD and EMPA-KIDNEY subsequently showed kidney-protective effects across broader CKD populations, including many patients without diabetes, thereby strengthening the biological and clinical rationale for SGLT2 inhibition as kidney-protective therapy (12,13).

In practice, SGLT2 inhibitors are especially valuable when heart failure or CKD is a dominant concern. Their glucose-lowering effect diminishes as eGFR falls, but cardiovascular and kidney benefits may persist even when glycemic efficacy is attenuated (1,2). Clinicians should counsel patients about genital mycotic infections, volume depletion, temporary interruption during prolonged fasting or acute illness when appropriate, and the uncommon but clinically important risk of euglycemic ketoacidosis. Risk mitigation is an integral part of evidence-based prescribing rather than a reason to avoid the class in suitable patients (1).

3.4. GLP-1 receptor agonists: glycemia, weight, cardiovascular and kidney outcomes

GLP-1 receptor agonists combine glucose-dependent insulinotropic activity with suppression of inappropriate glucagon secretion, delayed gastric emptying, and central effects on appetite. Their contemporary role is therefore both metabolic and cardiovascular. LEADER showed that liraglutide reduced major cardiovascular events in high-risk T2DM, while SUSTAIN-6 demonstrated cardiovascular benefit with injectable semaglutide in a similarly high-risk population (6,7).

The evidence base has continued to expand. The SOUL trial reported that oral semaglutide reduced major adverse cardiovascular events compared with placebo among

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

people with T2DM and established ASCVD, CKD, or both, confirming that cardiovascular benefit is not limited to injectable formulations (8). The FLOW trial further demonstrated that semaglutide improved major kidney outcomes in T2DM with CKD and slowed loss of kidney function, strengthening the role of GLP-1 receptor agonism in integrated cardiorenal-metabolic care (14).

From a practical perspective, GLP-1 RAs are particularly attractive when ASCVD and obesity coexist, when avoidance of hypoglycemia is important, or when substantial weight reduction is a therapeutic priority. Gastrointestinal adverse effects are common during dose escalation and can limit adherence. Gradual titration, counseling about meal size, and individualized management of nausea or constipation improve persistence. In people with pre-existing diabetic retinopathy and markedly elevated HbA1c, rapid glycemic improvement should prompt appropriate eye surveillance, particularly when potent therapy is initiated (1,7).

3.5. Dual GIP/GLP-1 receptor agonism: tirzepatide and the rise of high-efficacy incretin therapy

Tirzepatide is a dual agonist at glucose-dependent insulinotropic polypeptide and GLP-1 receptors. In SURPASS-2, tirzepatide produced greater HbA1c and body-weight reductions than semaglutide 1 mg in adults with T2DM inadequately controlled with metformin, illustrating the high metabolic efficacy of dual incretin pharmacology (4). The 2026 ADA Standards identify tirzepatide and semaglutide among the highest-efficacy therapies for both glucose and weight reduction (1).

Cardiovascular outcome evidence has also matured. SURPASS-CVOT compared tirzepatide directly with dulaglutide in patients with T2DM and ASCVD and established noninferiority for major adverse cardiovascular events, although superiority was not demonstrated (5). This distinction is important: tirzepatide has strong metabolic efficacy and acceptable cardiovascular safety relative to an active comparator with proven cardiovascular benefit, but clinical claims should remain aligned with the actual trial endpoint rather than extrapolated beyond the evidence.

The emergence of dual incretin therapy changes treatment sequencing. In a patient for whom obesity is a major driver of glycemic deterioration, cardiovascular risk, sleep apnea, mobility limitation, or quality-of-life impairment, a high-efficacy incretin strategy may be selected earlier rather than reserved for late treatment failure. This supports a shift from "add a second drug after failure" toward deliberate selection of therapy capable of achieving multiple treatment goals from the outset (1,3-5).

3.6. Finerenone and the expansion of diabetes pharmacotherapy beyond glucose lowering

Not all evidence-based pharmacotherapy in T2DM is glucose lowering. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduced CKD progression and cardiovascular events in patients with T2DM and CKD in FIDELIO-DKD (15). Its role demonstrates the broader concept of diabetes therapeutics: treatment should target the mechanisms and complications that determine long-term prognosis, not only hyperglycemia. In appropriate patients with albuminuric CKD already receiving standard renin-angiotensin system blockade, finerenone may be considered as part of layered kidney and cardiovascular risk reduction, with careful potassium and kidney-function monitoring (2,15).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

Table 2. Landmark outcome trials informing modern pharmacotherapy of type 2 diabetes

Trial / year	Intervention	Population	Principal finding	Clinical implication
EMPA-REG OUTCOME (2015)	Empagliflozin	T2DM + established CVD	Lower primary CV composite and mortality	Established CV benefit of SGLT2 inhibition
LEADER (2016)	Liraglutide	T2DM + high CV risk	Lower MACE	Established GLP-1 RA CV benefit
SUSTAIN-6 (2016)	Semaglutide s.c.	T2DM + high CV risk	Lower MACE; stroke signal prominent	Supports semaglutide CV benefit
DECLARE-TIMI 58 (2019)	Dapagliflozin	T2DM + ASCVD or risk factors	Lower CV death/HF hospitalization composite, driven by HF	Supports HF prevention across broad T2DM population
CREDENCE (2019)	Canagliflozin	T2DM + albuminuric CKD	Lower kidney failure / renal-CV composite	Established dedicated kidney protection in diabetic CKD
DAPA-CKD (2020)	Dapagliflozin	CKD with/without T2DM	Lower kidney/CV composite	Reinforced class-level kidney protection
FIDELIO-DKD (2020)	Finerenone	T2DM + CKD	Lower CKD progression and CV events	Adds non-glycemic cardiorenal therapy
SURPASS-2 (2021)	Tirzepatide vs semaglutide 1 mg	T2DM on metformin	Greater HbA1c and weight reduction with tirzepatide	Supports high-efficacy dual incretin strategy
EMPA-KIDNEY (2023)	Empagliflozin	Broad CKD population	Reduced kidney progression/CV death composite	Expanded SGLT2 kidney evidence
FLOW (2024)	Semaglutide s.c.	T2DM + CKD	Reduced major kidney outcomes and slowed eGFR decline	Strengthened GLP-1 RA kidney role

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

Trial / year	Intervention	Population	Principal finding	Clinical implication
SOUL (2025)	Oral semaglutide	T2DM + ASCVD and/or CKD	Lower MACE vs placebo	Extends CV efficacy to oral semaglutide
SURPASS-CVOT (2025)	Tirzepatide vs dulaglutide	T2DM + ASCVD	CV noninferiority; superiority not shown	Confirms CV safety vs active GLP-1 comparator

3.7. Insulin remains essential in selected clinical states

The availability of highly effective noninsulin agents does not eliminate the need for insulin. Insulin should be considered promptly in severe symptomatic hyperglycemia, catabolic states, suspected marked insulin deficiency, or clinical decompensation. It may also be required when individualized glycemic goals remain unmet despite rational combination therapy. Current guidance generally favors use of a GLP-1 RA or dual GIP/GLP-1 RA before intensifying to complex insulin regimens in many adults who do not have clear insulin deficiency, because incretin-based therapy can improve glycemia with less hypoglycemia and more favorable weight effects (1).

When insulin is initiated, other agents with proven cardiovascular, kidney, or weight benefits should not automatically be discontinued. Instead, the regimen should be simplified where possible, sulfonylurea exposure reassessed, and basal insulin titrated according to fasting glucose while avoiding overbasalization. Modern insulin therapy is therefore integrated with, rather than isolated from, contemporary cardiorenal-metabolic pharmacotherapy (1).

Figure 1. Phenotype-directed pharmacotherapy algorithm for type 2 diabetes




Figure 1. Phenotype-directed treatment algorithm derived from contemporary guideline principles (1-3).

4. DISCUSSION

4.1. Selecting therapy by dominant clinical phenotype

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

The most important practical implication of the evidence is that T2DM pharmacotherapy should begin with identification of the dominant treatment priority. For a patient with ASCVD, preventing myocardial infarction, stroke, and cardiovascular death may be more important than selecting the drug that produces the largest isolated HbA1c reduction. For a patient with heart failure, hospitalization prevention may dominate the choice. For a patient with CKD, preservation of kidney function may become the primary objective. For a patient with severe obesity and no established cardiorenal disease, achieving substantial and durable weight loss may produce the greatest long-term metabolic benefit. This phenotype-directed approach is explicitly reflected in current ADA recommendations (1,2).

Accordingly, the same HbA1c value can justify different pharmacologic strategies in different patients. An SGLT2 inhibitor may be chosen early in a patient with heart failure even if additional glucose lowering is modest. A GLP-1 RA may be prioritized in a patient with ASCVD and obesity. Tirzepatide may be selected where very high glycemic and weight efficacy are needed, provided there are no contraindications and the patient can tolerate and access treatment. Metformin may remain central in a younger patient with newly diagnosed disease, limited comorbidity, modest hyperglycemia, and cost constraints. This is individualized pharmacotherapy in a clinically meaningful sense, not simply personalization of an HbA1c target.

4.2. Rational combination therapy and sequencing

Combination therapy is increasingly justified earlier in the disease course when baseline HbA1c is sufficiently above target or when multiple outcomes must be addressed simultaneously. Mechanistically complementary regimens can provide additive glucose lowering without proportionally increasing hypoglycemia. Metformin plus an SGLT2 inhibitor, metformin plus a GLP-1 RA, or an SGLT2 inhibitor combined with a GLP-1 RA are common examples. In patients with concomitant ASCVD and CKD, combined SGLT2 and GLP-1 receptor agonist therapy may be clinically attractive because each class addresses overlapping but distinct outcome domains (1,2).

Therapeutic sequencing should also minimize treatment burden and adverse effects. Adding multiple drugs without deprescribing can produce complexity, reduce adherence, and increase cost. When a potent incretin therapy achieves substantial glycemic improvement, doses of insulin or sulfonylureas may need reduction to decrease hypoglycemia risk. Similarly, the introduction of insulin should prompt reassessment of medications that add hypoglycemia risk but little organ protection. Treatment intensification and treatment simplification are therefore both components of optimal pharmacotherapy.

4.3. Safety, tolerability, adherence and access

Outcome benefits cannot be realized when treatment is not tolerated or cannot be obtained. SGLT2 inhibitors require education about genital infections, hydration, sick-day management, and ketoacidosis risk. GLP-1 RAs and tirzepatide require counseling about gastrointestinal adverse effects and gradual dose escalation. Finerenone requires potassium surveillance. Insulin and sulfonylureas require specific hypoglycemia prevention strategies. These safety considerations should be incorporated at treatment initiation rather than addressed only after an adverse event occurs (1,15).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

Cost and access are also clinical variables. The efficacy of a high-cost therapy is irrelevant if the patient cannot sustain treatment. The ADA therefore explicitly includes cost and access in shared decision-making (1). For some patients, lower-cost medications such as metformin, sulfonylureas, or human insulin may be the most realistic strategy, but their risks should be actively managed. Evidence-based care should seek the best achievable balance between biological efficacy, proven outcome benefit, affordability, and long-term adherence.

4.4. Weight management as a core therapeutic objective

Weight management has moved from a secondary consideration to a core component of T2DM treatment. Excess adiposity worsens insulin resistance, contributes to sleep apnea and fatty liver disease, increases cardiovascular risk, and can accelerate the need for medication escalation. The high weight-loss efficacy of semaglutide and tirzepatide makes it possible to treat hyperglycemia and obesity through the same pharmacologic strategy in appropriately selected patients (1,3,4).

Importantly, medication selection should distinguish between weight neutrality and clinically meaningful weight reduction. DPP-4 inhibitors and metformin may avoid additional weight gain, but incretin-based therapies can achieve a substantially larger weight response. Conversely, sulfonylureas, insulin, and thiazolidinediones may promote weight gain and should be used thoughtfully when weight is a major treatment priority. The modern aim is therefore not simply to avoid weight gain but, when appropriate, to achieve sufficient weight loss to improve metabolic disease burden.

Table 3. Practical phenotype-directed selection of pharmacotherapy

Clinical phenotype / priority	**Preferred pharmacologic direction**	**Why**	**Key monitoring**
Established ASCVD / high CV risk	GLP-1 RA with CV benefit and/or SGLT2 inhibitor with CV benefit	Reduces cardiovascular events; class choice can reflect HF/CKD/weight priorities	CV status, renal function, tolerability
Heart failure (HFrEF or HFpEF)	SGLT2 inhibitor	Strong evidence for reduction in HF hospitalization	Volume status, kidney function, ketoacidosis risk
CKD / albuminuria	SGLT2 inhibitor; consider GLP-1 RA; finerenone when indicated	Slows kidney disease progression and reduces CV risk	eGFR, albuminuria, potassium for finerenone
Obesity / major weight priority	Tirzepatide or high-efficacy GLP-1 RA	Largest combined glycemic and weight effects among current noninsulin options	GI tolerability, weight trajectory, eye status when rapid A1C fall is expected

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

Clinical phenotype / priority	Preferred pharmacologic direction	Why	Key monitoring
High hypoglycemia vulnerability	Metformin, SGLT2 inhibitor, GLP-1 RA, DPP-4 inhibitor	Low intrinsic hypoglycemia risk	Glucose profile; adjust insulin/sulfonylureas if combined
Severe hyperglycemia / catabolic symptoms	Insulin, often with continuation of organ-protective agents	Rapid correction of metabolic decompensation	Glucose, ketones when indicated, hypoglycemia, dose titration
Major cost/access constraints	Metformin; selected sulfonylurea; human insulin where necessary	Affordability and continuity may outweigh convenience	Hypoglycemia, weight, adherence, access to supplies

4.5. Monitoring, deintensification and prevention of therapeutic inertia

Effective pharmacotherapy requires planned follow-up rather than simple prescription of a drug. After initiation or dose escalation, clinicians should reassess glycemic response, weight trajectory, adverse effects, adherence, renal function when relevant, and whether the selected agent is actually addressing the original clinical priority. HbA1c remains an important measure of average glycemia, but it should be interpreted together with hypoglycemia, glucose variability, body weight, blood pressure, kidney function, albuminuria, and cardiovascular status. The 2026 ADA framework explicitly emphasizes repeated reassessment and avoidance of therapeutic inertia (1).

Deintensification is equally important. A patient who begins a potent GLP-1 RA or tirzepatide while receiving insulin or a sulfonylurea may develop a substantially lower glucose requirement. Failure to reduce the dose of hypoglycemia-producing therapy can convert successful treatment intensification into preventable hypoglycemia. Conversely, persistent hyperglycemia despite adequate adherence should trigger timely escalation rather than prolonged exposure to an ineffective regimen. The appropriate direction of change—intensification or simplification—depends on the patient's current risk profile and therapeutic response.

Kidney function changes also require context-specific interpretation. SGLT2 inhibitors may produce an early hemodynamic fall in eGFR that is distinct from progressive kidney injury, while their longer-term effect is kidney protective in appropriate patients (11-13). Finerenone requires potassium surveillance because hyperkalemia can limit therapy (15). GLP-1 RAs and tirzepatide require monitoring of gastrointestinal tolerability and nutritional intake, especially when weight loss is rapid. In older adults, frailty, cognitive impairment, polypharmacy, and limited life expectancy may justify less stringent glycemic goals and simplification of regimens that impose excessive hypoglycemia or treatment burden (1).

Therapeutic inertia can occur in two directions: failure to intensify despite persistent hyperglycemia and failure to remove unnecessary therapy after treatment goals have been exceeded or priorities have changed. Modern pharmacotherapy should therefore be understood as a dynamic cycle rather than a permanent ladder. The treatment plan should be deliberately revisited whenever new ASCVD, heart failure, CKD, obesity-related

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 19.09.2026 Accepted 20.09.2026 Online 24.09.2026

complications, recurrent hypoglycemia, financial barriers, or major changes in patient preferences emerge.

Table 4. Practical monitoring priorities after initiation of major pharmacologic classes

Therapy	Early follow-up focus	Ongoing monitoring	When to reconsider or modify
Metformin	GI tolerance; renal function; adherence	HbA1c; eGFR; periodic vitamin B12 in long-term use/risk states	Persistent intolerance, significant renal decline, inadequate efficacy
SGLT2 inhibitor	Volume status; genital symptoms; education on ketoacidosis risk	eGFR; albuminuria when CKD present; HF/renal outcomes	Recurrent ketoacidosis, severe intolerance, acute illness requiring temporary interruption
GLP-1 RA	Nausea, vomiting, satiety, dose-escalation tolerance	HbA1c; weight; CV/renal status; nutritional adequacy	Persistent GI toxicity, excessive weight loss, inability to adhere/access therapy
Tirzepatide	GI tolerance; glucose response if combined with insulin/SU	HbA1c; weight; hypoglycemia risk from background drugs	Need to reduce insulin/SU; intolerance; treatment burden or access problems
Finerenone	Potassium and eGFR	Potassium, eGFR, albuminuria	Hyperkalemia or clinically important renal deterioration
Insulin	Hypoglycemia; injection technique; titration	Glucose profile/CGM where available; HbA1c; weight	Overbasalization, recurrent hypoglycemia, opportunity to simplify regimen

4.6. Special clinical situations and treatment burden

Older adults and patients with multimorbidity illustrate why pharmacologic efficacy cannot be separated from feasibility. A regimen that is ideal in a randomized trial may be unsuitable for a patient with frailty, recurrent falls, impaired vision, cognitive decline, or dependence on caregivers. In such circumstances, reducing hypoglycemia risk and simplifying administration may be more important than maximizing HbA1c reduction. Long-acting agents with low intrinsic hypoglycemia risk can be advantageous, but gastrointestinal effects, dehydration risk, cost, and ability to manage injections must still be considered (1).

Patients with CKD require particularly careful dose selection and monitoring because kidney function affects both drug handling and hypoglycemia vulnerability. At the same time, CKD is precisely the setting in which SGLT2 inhibitors, GLP-1 RAs, and finerenone

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 | Received 19.09.2026 | Accepted 20.09.2026 | Online 24.09.2026

may provide outcome benefits that extend beyond glucose lowering (1,2,11-15). This creates a clinical paradox: the patient at greatest medication-related risk may also have the greatest potential benefit from appropriately layered therapy. The solution is structured monitoring, not therapeutic nihilism.

Finally, treatment burden should be treated as a measurable clinical outcome. Multiple injections, complex titration schedules, frequent glucose checks, adverse effects, prior authorization requirements, and high out-of-pocket costs can undermine adherence even when the biological rationale is strong. Shared decision-making should therefore identify which outcomes matter most to the patient and which treatment burdens are acceptable. A slightly less potent regimen that can be sustained may produce better real-world outcomes than a theoretically optimal regimen that is repeatedly interrupted.

Figure 2. Comparative therapeutic domains of major glucose-lowering drug classes




Figure 2. Comparative therapeutic domains of major glucose-lowering classes. The figure is conceptual and should not be interpreted as a pooled quantitative comparison across heterogeneous trials (1-5).

4.7. Future directions: integrated cardiometabolic pharmacology

The next phase of T2DM therapeutics is likely to be defined by integrated cardiometabolic pharmacology rather than isolated glucose-lowering mechanisms. Multi-agonist incretin strategies, more convenient oral peptide delivery, personalized risk prediction, and earlier use of combination therapy may further shift treatment away from reactive escalation. The SOUL trial already demonstrates that an oral GLP-1 RA formulation can provide cardiovascular efficacy in high-risk T2DM (8), while SURPASS-CVOT provides outcome-level cardiovascular safety data for dual GIP/GLP-1 receptor agonism (5).

Equally important is the convergence of diabetes, obesity, heart failure, and kidney disease treatment. A single patient may appropriately receive an SGLT2 inhibitor for heart-

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 19.09.2026 | Accepted 20.09.2026 | Online 24.09.2026

failure and kidney protection, a GLP-1 RA or dual incretin agent for glycemia, weight, and ASCVD risk reduction, renin-angiotensin system blockade for albuminuric kidney disease, and finerenone for residual kidney and cardiovascular risk. The central challenge is no longer lack of effective therapies; it is selecting, sequencing, monitoring, and sustaining the right combination for the individual patient.

5. CONCLUSION

Evidence-based pharmacotherapy of T2DM has evolved from a stepwise glucose-lowering algorithm into a multidimensional strategy aimed at improving glycemia, reducing body weight, and preventing cardiovascular and kidney events. The 2026 ADA Standards support early use of SGLT2 inhibitors and/or GLP-1 receptor agonists when ASCVD, heart failure, or CKD is present, regardless of whether additional HbA1c lowering is required (1,2). Tirzepatide and semaglutide represent highly effective options when substantial glucose and weight reduction are priorities, while recent outcome trials extend the evidence base for oral semaglutide and provide cardiovascular safety data for tirzepatide (4,5,8). Kidney outcome trials support SGLT2 inhibition as foundational therapy in CKD and show additional kidney protection with semaglutide and finerenone in appropriate patients (11-15). Metformin, conventional agents, and insulin remain important when chosen according to clinical context, safety, affordability, and treatment burden. The most effective contemporary strategy is therefore phenotype-directed, outcome-oriented, and repeatedly reassessed over time.

REFERENCES

1. American Diabetes Association Professional Practice Committee for Diabetes. (2026). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S183-S215. https://doi.org/10.2337/dc26-S009
2. American Diabetes Association Professional Practice Committee for Diabetes. (2026). 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S216-S245. https://doi.org/10.2337/dc26-S010
3. Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., et al. (2022). Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 45(11), 2753-2786. https://doi.org/10.2337/dci22-0034
4. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385, 503-515. https://doi.org/10.1056/NEJMoa2107519
5. SURPASS-CVOT Investigators. (2025). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. New England Journal of Medicine, 393, 2409-2420. https://doi.org/10.1056/NEJMoa2505928
6. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375, 311-322. https://doi.org/10.1056/NEJMoa1603827

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 19.09.2026 | Accepted 20.09.2026 | Online 24.09.2026

7. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375, 1834-1844. https://doi.org/10.1056/NEJMoa1607141
8. McGuire, D. K., et al. (2025). Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2501006
9. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373, 2117-2128. https://doi.org/10.1056/NEJMoa1504720
10. Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380, 347-357. https://doi.org/10.1056/NEJMoa1812389
11. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380, 2295-2306. https://doi.org/10.1056/NEJMoa1811744
12. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
13. The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388, 117-127. https://doi.org/10.1056/NEJMoa2204233
14. Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391, 109-121. https://doi.org/10.1056/NEJMoa2403347
15. Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., et al. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine, 383, 2219-2229. https://doi.org/10.1056/NEJMoa2025845